Medmain Speaks

Deep Learning Models for Gastric Signet Ring Cell Carcinoma Classification in Whole Slide Images

A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy

Medmain Co., Ltd. (Headquarters: Fukuoka Prefecture, Fukuoka City, CEO: Osamu Iizuka, hereinafter referred to “Medmain”), a provider of “PidPort” pathological diagnosis support solutions, has succeeded in developing an artificial intelligence model to classify lung cancer subtypes in lung biopsy specimens using Deep Learning, which enables the sub-classification of the macarcinoma). A dissertation

We a happy to announce that we have raised approximately 1.1 billion yen through a private placement of new shares by multiple hospital groups, venture capitalists, businesses, and private investors. With the recent demand for the rapid development of a diagnostic system after the COVID-19 pandemic, Medmain Inc. will continue to support medical professionals across the country, especially those who are on the front lines of pathology diagnosis. About Fundraising

Deep Learning has been used in various medical fields recently especially in radiology and pathology where medical image recognition has been used frequently. We have announced in January 2020 the establishment of an AI model to detect epithelial tumors in the stomach and colon, and this has been published by Scientific Reports. (Scientific Reports 2020, volume 10, Article (number: 1504) We are so pleased to announce that on June 9th, 2020, our paper co-authored by the doctors from the National Hospital Organization Kyushu Medical Center and members of Medmain Inc.